Venous Congestion in Surgical Flaps
FDA-cleared application: medicinal leech therapy to relieve venous congestion in compromised tissue flaps awaiting vascular ingrowth.
Краткая информация для пациента
- Есть ли FDA-допуск для этого показания?
- Yes — FDA-cleared under K040187 (June 21, 2004) for medicinal leech application to relieve venous congestion in microsurgical reconstructive procedures.
- Какие доказательства существуют?
- This is the one situation where the FDA has officially cleared medicinal leeches as a medical device. Hospital studies (retrospective series totaling 400+ patients) show that when leech therapy is started within 24 hours of congestion, 70 to 85 percent of threatened flaps survive that would otherwise have been lost. It does not work for flaps with poor artery blood flow — that is a surgical problem leeches cannot solve.
- Основные риски
- Heavy bleeding from the bite site for 6 to 10 hours after each leech detaches
- Need for a blood transfusion if many leeches are used over several days (about 1 in 5 to 1 in 3 patients)
- Aeromonas hydrophila infection from the leech's gut bacteria (your team gives a preventive antibiotic such as ciprofloxacin)
- Loss of the flap anyway if the underlying artery problem cannot be fixed
- Allergic reaction to leech saliva proteins (rare but possible)
- Scarring from the bite marks once they heal
- Кому не следует это рассматривать
- Patients on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, or heparin
- People with hemophilia or any inherited bleeding disorder
- Patients with severe anemia (hemoglobin under 10 g/dL) who cannot tolerate more blood loss
- Patients with an active bloodstream infection or sepsis
- Patients allergic to ciprofloxacin or other antibiotics needed to prevent Aeromonas infection
- Patients whose flap has lost arterial blood supply (this needs surgical repair first, not leeches)
- О чём спросить врача
- Is the problem with my flap a vein issue or an artery issue? Leeches only help with vein problems.
- What antibiotic will I get to prevent Aeromonas infection, and how long will I take it?
- How often will my blood count be checked, and at what hemoglobin level would you transfuse me?
- What is the expected timeline — how many days of leech therapy do you estimate before the flap can drain on its own?
- What signs should my family and I watch for that would mean the treatment is not working?
- Who is responsible for placing and removing the leeches, and how often will they check on me?
- What happens to the used leeches afterward, and is there any disposal concern?
- Когда срочно обратиться за медицинской помощью
- Bleeding from a bite site that soaks through more than one dressing per hour, or any bleeding lasting more than 24 hours after the leech detached
- Spreading redness, warmth, swelling, or pus around the bite area or the flap
- Fever over 38.0 C / 100.4 F or chills
- The flap becoming darker, colder, or harder despite leech therapy
- Hives, swelling of the face or tongue, difficulty breathing, or any sign of allergic reaction
Что это НЕ означает
- It does not mean the flap is guaranteed to survive — even with leeches, about 15 to 30 percent of severely congested flaps are still lost, usually because of an artery problem that leeches cannot fix.
- It does not mean leeches cure anything by themselves — they buy time (about 3 to 7 days) while your body grows new veins into the flap.
- It does not mean this is a treatment you can do at home — it is an inpatient hospital therapy with continuous monitoring of blood counts.
- It does not mean medicinal leeches are the same as wild leeches — they are FDA-cleared, lab-raised under sterile conditions, and used only once.
Перекрёстные ссылки безопасности
Clinical Profile
- Category
- surgical reconstruction
- ICD-10
- T87.40, T87.41, T87.42, T87.43, T87.44, I87.8
- Safety tier
- high
Evidence Summary
Venous congestion in pedicled and free flaps is the most common cause of postoperative flap failure, occurring in 5-10% of microsurgical reconstructions. Hirudo medicinalis received FDA clearance (K040187, June 21 2004) specifically for relief of venous congestion. The mechanism is twofold: mechanical drainage from the bite wound (oozing for 6-10 hours after detachment) and pharmacologic action of hirudin, calin, and hyaluronidase reducing local thrombogenesis. Multiple retrospective series demonstrate flap salvage rates of 70-85% when initiated within 24 hours of congestion onset. Failure to thrive remains driven by arterial compromise (which leeches cannot address) and delayed initiation.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Whitaker IS et al. (2012), n=277 · PMID 22407551 · ASH analysis →
- Nguyen MQ et al. (2012), n=39 · PMID 22473683 · ASH analysis →
- Chepeha DB et al. (2002), n=8 · PMID 12162779 · ASH analysis →
- Systematic Review: 1 (33%)
- Cohort: 1 (33%)
- Case Series: 1 (33%)
Detailed Trial Entries
19 trials indexed in the ASH RCT Library with full Study Profile, GRADE rating, and clinical implications:
- Prospective Randomized Pilot Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric Extracorporeal Membrane Oxygenation
McMichael A, Weller J, Li X, Hatton L, Zia A, Raman L (2024) · Pediatric Critical Care Medicine · n=30 · GRADE low
- Efficacy of Bivalirudin for Therapeutic Anticoagulation in COVID-19 Patients Requiring ECMO Support
Trigonis R, Smith N, Porter S, Anderson E, Jennings M, Kapoor R, Hage C, Moiz S, Garcia J, Rahman O (2021) · Journal of Cardiothoracic and Vascular Anesthesia · n=42 · GRADE low
- Bivalirudin versus heparin anticoagulation in patients receiving extracorporeal membrane oxygenation
Huang D, Guan Q, Qin J, Shan R, Wu J, Zhang C (2022) · Perfusion · n=1232 · GRADE low
- Heparin-based versus bivalirudin-based anticoagulation in pediatric extracorporeal membrane oxygenation: A systematic review
Valdes CA, Sharaf OM, Bleiweis MS, Jacobs JP, Mumtaz M, Sharaf RM, Jeng EI, Peek GJ (2023) · Frontiers in Medicine · n=313 · GRADE low
- Comparison of Bivalirudin Versus Heparin for Anticoagulation During Extracorporeal Membrane Oxygenation
Hasegawa D, Sato R, Prasitlumkum N, Nishida K, Keaton B, Acquah SO, Im Lee Y (2022) · ASAIO Journal · n=0 · GRADE low
- Heparin Versus Bivalirudin for Anticoagulation in Adult Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-Analysis
Wieruszewski PM, Macielak SA, Nei SD, Moman RN, Seelhammer TG, Nabzdyk CGS, Gerberi DJ, Mara KC, Hooten WM, Wittwer ED (2022) · ASAIO Journal · n=0 · GRADE low
- Bivalirudin or heparin for systemic anticoagulation during pediatric extracorporeal membrane oxygenation: Multicenter retrospective study
Hamzah M, Seelhammer TG, Beshish AG, Byrnes J, Yabrodi M, Szadkowski A, Lutfi R, Andrijasevic N, Hock K, Worley S, Macrae DJ (2023) · Thrombosis Research · n=225 · GRADE low
- Is bivalirudin an alternative anticoagulant for extracorporeal membrane oxygenation (ECMO) patients? A systematic review and meta-analysis
Li DH, Sun MW, Zhang JC, Zhang C, Deng L, Jiang H (2021) · Thrombosis Research · n=0 · GRADE low
- Bivalirudin Monitoring in Pediatric Ventricular Assist Device and Extracorporeal Membrane Oxygenation: Analysis of Single-Center Retrospective Cohort Data 2018-2022
Engel ER, Perry T, Block M, Palumbo JS, Lorts A, Luchtman-Jones L (2024) · Pediatric Critical Care Medicine · n=22 · GRADE low
- Impact of inflammation and steroids on anti-coagulation in children supported on a ventricular assist device
Brandewie K, Lorts A, Luchtman-Jones L, Gao Z, Geer B, Villa C, Perry T (2024) · Journal of Artificial Organs · n=10 · GRADE very-low
- Improved outcomes with pulsatile paracorporeal ventricular assist device support in children: A single-center experience
Iaprintsev V, Fricke TA, Buratto E, Zubritskiy A, Perrier S, Eastaugh L, Barnes C, Sheridan B, Naimo PS, Brizard CP, Mathew J, Konstantinov IE (2025) · JTCVS Open · n=75 · GRADE low
- Comparison of two pediatric cases requiring the use of bivalirudin during cardiopulmonary bypass
Bryant ME, Regan WL, Fynn-Thompson F, Hoganson D, Nasr VG, Zaleski K, Faella K, Matte GS (2018) · Perfusion · n=2 · GRADE very-low
- Catheter-Directed Bivalirudin for Local Anticoagulation and Clot Dissolution in Children Requiring Mechanical Circulatory Support
Chaudhry-Waterman N, Schardt TQ, Soderstrom RM, Warren BB, Buckvold S, Morgan G, Kim JS (2025) · ASAIO Journal · n=3 · GRADE very-low
- Reconstruction of the soft tissue defects of foot and ankle with neural-island flaps: mono-institutional case series
Sonmez E, Safak T (2011) · Journal of Reconstructive Microsurgery · n=20 · GRADE very-low
- Flap infection associated with medicinal leeches in reconstructive surgery: two new drug-resistant organisms
Bibbo C, Fritsche T, Stemper M, Hall M (2013) · Journal of Reconstructive Microsurgery · n=2 · GRADE very-low
- Reverse posterior interosseous flap for defects of the dorsal ulnar wrist using previously burned and recently grafted skin
Baylan JM, Chambers JA, McMullin N, Fletcher JL, Sinha I, Lundy J, King BT, Chan RK (2015) · Burns · n=3 · GRADE very-low
- Hirudins and fenestrins of the African medicinal leech Asiaticobdella fenestrata
Schulz L, Tolksdorf C, Rauch BH, Kvist S, Müller C (2025) · Parasitology Research · n=0 · GRADE very-low
- Draft genome sequences of Hirudo medicinalis and salivary transcriptome of three closely related medicinal leeches
Babenko VV, Podgorny OV, Manuvera VA, Kasianov AS, Manolov AI, Grafskaia EN, Shirokov DA, Kurdyumov AS, Vinogradov DV, Nikitina AS, Kovalchuk SI, Anikanov NA, Butenko IO, Pobeguts OV, Matyushkina DS, Rakitina DV, Kostryukova ES, Zgoda VG, Baskova IP, Trukhan VM, Gelfand MS, Govorun VM, Schiöth HB, Lazarev VN (2020) · BMC Genomics · n=0 · GRADE very-low
- Destructive Mold Osteomyelitis of the Wrist Caused by Scedosporium - A Case Report
Bo C, Conen A, Giacalone M, Marti R, Grobholz R, Seeger H, Klein HJ, Plock JA, Frueh FS (2026) · Journal of Clinical Medicine · n=1 · GRADE very-low
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Arterial insufficiency to the flap (must address before leeching)
- Patient unable to consent to potential transfusion requirement
Related ASH Compounds
Leech-derived molecules implicated in this condition, each profiled in the ASH compound registry:
Related Conditions
Microsurgical Replantation (Digit / Ear / Scalp)
FDA-cleared application: post-replantation venous decompression in digits, ears, scalp, and partial avulsion injuries.
Breast Reconstruction Flap Salvage
FDA-cleared application: venous decompression of compromised DIEP, TRAM, and latissimus dorsi flaps in post-mastectomy reconstruction.